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Abstract
Twenty percent of patients with Cancer Associated Thrombosis receive an inferior vena cava filter annually. Insertion is guided by
practice guidelines, which do not specify or discuss the use of inferior vena cava filters in malignancy. Adherence to these guidelines
is known to be variable. We aimed to see if there was consistent management of venous thromboembolism among Medical
Oncologists/Haematologists and Respiratory Physicians, with respect to inferior vena cava filter use in the setting of suspected and
confirmed malignancy. Medical Oncologists, Haematologists and Respiratory Physicians were surveyed with four theoretical cases.
Case 1 concerns a patient who develops a pulmonary embolism following spinal surgery. Cases 2 and 4 explore the use of inferior
vena cava filters in the setting of malignancy. Case 3 covers the role of inferior vena cava filters in recurrent thrombosis despite
systemic anticoagulation. There were 56 responses, 32 (57%) Respiratory Physicians and 24 (43%) Haematologists/Oncologists.
Respiratory Physicians were significantly more likely to insert an inferior vena cava filter in case 1 (p ¼ 0.04) whilst Haematologists/
Medical Oncologists were more likely to insert an inferior vena cava filter in case 3 (p ¼ 0.03). No significant differences were
found in cases 2 and 4. There were significant disparities in terms of type and timing of anticoagulation. Consistency of recommendations with guidelines was variable likely in part because guidelines are themselves inconsistent. The heterogeneity in
responses highlights the variations in venous thromboembolism management, especially in Cancer Associated Thrombosis.
International Societies should consider addressing inferior vena cava filter use specifically in the setting of Cancer Associated
Thrombosis. Collaboration between interested specialities would assist in developing consistent, evidence-based guidelines for the
use of inferior vena cava filters in the management of venous thromboembolism.
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Introduction
Venous thromboembolism (VTE) is a potentially lethal
event. Systemic anticoagulation is the main modality of
treatment. Inferior vena cava ﬁlters (IVCFs) may be used
as an adjunct to anticoagulation or when anticoagulation is
contraindicated.
The development of retrievable IVCFs led to increased use
when compared to permanent IVCFs.1,2 Few prospective

controlled studies, with limited quality of evidence, exist
regarding the eﬃcacy and safety of IVCFs.3 Guidelines published by diﬀerent international societies are inconsistent,
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with no recommendations made for IVCFs and Cancer
Associated Thrombosis (CAT) (Fig. 1).4–11
In 2010, after reviewing 921 adverse events over a ﬁveyear period, the US Food and Drug Administration (FDA)
issued a safety statement recommending ‘that implanting
physicians and clinicians responsible for the ongoing care
of patients with retrievable IVCFs consider removing the
ﬁlter as soon as protection from pulmonary embolism is
no longer needed’.12 This resulted in a fall in the rate of
IVCF placement.2 Retrievable IVCFs result in more frequent complications than their permanent counterparts
with complication rates directly linked to the length of
time the IVCF remains in situ.13

Craven et al.

The burden of VTE in malignancy is high, with VTE
accounting for approximately 9% of cancer deaths.14
Furthermore, patients with CAT tend to have more advanced
cancer correlating to an increased bleeding risk and a higher
rate of recurrent VTE, both of which are considerations for
IVCF insertion.8,9,15,16 It is estimated that 30,000–40,000 ﬁlters are deployed annually in patients with malignancy in the
US alone,17 accounting for over 30% of total IVCF placements.2 In one study, 25% of patients diagnosed with a
Pulmonary Embolism (PE) in association with a solid
organ malignancy received an IVCF.18 The most common
reason provided for their use was a contraindication to

Fig. 1. Summary of recommendations for IVCF insertion from international societies.
BCSH: British Committee for Standards in Haematology; LMWH: low molecular weight heparin.

Pulmonary Circulation
anticoagulation (39%); however, no indication was documented in 23%.
We have previously published our experience with IVCF
use at our centre where we found a preponderance of use
outside established guidelines.19 This drove our interest in
understanding how Australian specialists approached
common clinical dilemmas around IVCF use in VTE.
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Survey development

Methods

Based on the available guidelines for the use of IVCFs, four
cases were created, each with a series of multiple-choice
questions. The scenarios presented were designed to consider the type and timing of anticoagulation and/or whether
IVCFs would be recommended, including situations in
which the guidelines may be considered to provide conﬂicting recommendations (supplementary Appendix A).
Broadly the cases may be summarised as follows:

We surveyed specialists involved in VTE management on
four ﬁctional cases adapted from patients seen in our hospital to ascertain whether there was a consistency in the
clinical approach and how closely this aligned with existing
guidelines (Fig. 2).

1. A patient following cervical laminectomy who develops a symptomatic PE and Deep Vein Thrombosis
(DVT) three days post operatively – presenting a conﬂict between the risk of bleeding and the need for
urgent anticoagulation.

Fig. 2. Case descriptions.
VTE: venous thromboembolism.

4

| Dilemmas in anticoagulation and use of Inferior Vena Cava Filters

2. A patient with a recently diagnosed gynaecological malignancy who develops a PE before a planned procedure –
highlighting the perioperative management of known
recent VTE in association with need for semi-urgent surgical resection of a malignancy.
3. A patient with recurrent VTE despite adequate anticoagulation – highlighting anticoagulation in recurrent VTE
and need for further investigation for occult malignancy.
4. A patient with known metastatic malignancy with extensive
VTE (both a large PE and extensive DVT) on myelosuppressive chemotherapy – highlighting therapeutic options,
including type of anticoagulation and potential use of IVCF.

Survey distribution
Ethical approval was obtained from the St John of God
Human Research Ethics Committee. The survey was then
circulated electronically to Respiratory Physicians, Medical
Oncologists and Haematologists at major teaching hospitals
in Western Australia, New South Wales and Victoria, via
heads of departments of several institutions.

Statistical analysis
Odds ratio, for inserting an IVCF compared with choosing
not to, are reported with their 95% conﬁdence interval from
separate univariable logistic regression models. All analyses
were conducted using Stata v 15.0. A p value of <0.05 was
considered statistically signiﬁcant.

Results
There were 56 complete survey responses from 32
Respiratory Physicians (57%) and 24 Haematologists/
Medical Oncologists (43%) with a response rate of 66%.
All Haematologists surveyed had an interest in thrombosis.

Case 1: symptomatic PE and DVT three days post cervical
laminectomy
Of the physicians surveyed, half chose to prescribe anticoagulation immediately, with half choosing to delay anticoagulation.
Intravenous (IV) heparin was the most commonly prescribed
anticoagulant. Thirty physicians (56%) chose to insert an
IVCF, all retrievable and to be removed within six months
(Table 1).
Those who delayed anticoagulation were eight times
more likely to insert an IVCF than those who were anticoagulated immediately (p < 0.05).

Case 2: development of PE before a planned procedure
for gynaecologic malignancy
Thirty-seven physicians (66%) recommended deferring the
surgery for 1–3 weeks, with a further 19 (34%) respondents
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recommending delaying the surgery for 4–6 weeks. Twentyone (38%) (13 Respiratory/8 Haematologist/Oncologists)
recommended the insertion of an IVCF (Table 1).
Numerically clinicians recommending deferred surgery
were more likely to recommend IVCF insertion, but this
did not reach statistical signiﬁcance (p ¼ 0.277) (Table 2).

Case 3: recurrent VTE despite adequate anticoagulation
The majority of respondents (82%) chose to switch the
patient to low-molecular-weight heparin (LMWH, n ¼ 46)
either immediately (n ¼ 29 (63%) or after IV heparin
(n ¼ 17 (37%)), nine (16%) chose to switch to warfarin usually after IV heparin (n ¼ 8) with only one person choosing
to continue the direct oral anticoagulant (DOAC).
Eleven respondents (20%) chose to insert an IVCF, 10
(91%) of which were retrievable (50% electing to retrieve
within six months). Ten (91%) of these respondents opted to
switch to LMWH, while one (9%) continued with the
DOAC (Table 1).
The development of a recurrent VTE despite anticoagulation raises the suspicion of an occult malignancy. We
asked respondents what (if any) investigations they would
arrange in this circumstance. Details of recommended further investigations are shown in Fig. 3. Most respondents
elected to screen for occult malignancy.

Case 4: metastatic malignancy with extensive VTE
This case highlights the management of extensive VTE in
the setting of known solid organ malignancy. Only three
(7%) respondents recommended management with a
DOAC. The remainder (93%) chose to treat either with
LMWH initially or IV heparin initially then transitioning
to LMWH. Of the 12 respondents (21%) who recommended
insertion of an IVCF, four (33%) chose a permanent ﬁlter
(Table 1).

Differences between specialties
Compared
to
Haematology/Oncology
Physicians,
Respiratory Physicians were signiﬁcantly more likely to
insert an IVCF for case 1 (PE post-surgery), and less likely
to do so for case 3 (recurrent VTE on anticoagulation). No
statistical diﬀerence was noted between the specialties in cases
2 and 4 with regards to IVCF insertion (Table 3).

Discussion
The use of IVCFs has remained topical in recent years since
an FDA safety statement and a 2015 RCT which recommended against their use where anticoagulation could be
more eﬀective.12,20 Furthermore, the indications for IVCF
use in patients with malignancy-associated VTE is complicated by a lack of prospective clinical trial data to guide
decision making.

Pulmonary Circulation
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Table 1. Survey responses for each case.
Case responses
Case 1
Timing to anticoagulation (says post-surgery)
Day 3 (on diagnosis of VTE)
Days 4–10
Choice of anticoagulation
IV heparin Infusion
LMWH (Treatment dose)
LMWH (Prophylactic dose)
DOAC
VKA
Choice of anticoagulation
Yes
Permanent
Retrievable
No
Case 2
Timing to surgery
1–3 weeks
4–6 weeks
> 6 weeks
Choice of anticoagulation
IV heparin infusion cease 4–6 h before surgery
LMWH (treatment dose) cease 24 h before surgery
Decision to insert an IVCF
Yes
Permanent
Retrievable
No
Case 3
Choice of anticoagulation
Vitamin K antagonist (VKA)
DOAC
LMWH
IV heparin followed by DOAC
IV heparin followed by LMWH
IV heparin followed by VKA
Decision to insert an IVCF
Yes
Permanent
Retrievable
No
Case 4
Choice of anticoagulation
Vitamin K antagonist (VKA)
DOAC
LMWH
IV heparin followed by DOAC
IV heparin followed by LMWH
IV heparin followed by VKA

Respiratory
(n ¼ 32)

Haematology/oncology
(n ¼ 24)

Total
(n ¼ 56)

15 (267%)
17 (30.3%)

16 (28.5%)
8 (14.2%)

31 (55%)
25 (45%)

19
6
6
1
0

19
3
2
0
0

38
9
8
1
0

(34%)
(10.7%)
(10.7%)
(1.7%)
(0%)

(34%)
(5.3%)
(3.5%)
(0%)
(0%)

(68%)
(16%)
(14%)
(2%)
(0%)

21 (37.5%)
0 (0%)
21 (38%)
11 (19.6%)

9 (16%)
0 (0%)
9 (34%)
15 (26.7%)

26 (46%)

23 (41%)
9 (16%)
0 (0%)

14 (25%)
10 (17.8%)
0 (0%)

37 (66%)
19 (34%)
0 (0%)

19 (34%)
13 (23.2%)

11 (19.6%)
13 (23.2%)

30 (54%)
26 (46%)

13 (23.2%)
1 (1.7%)
12 (21.4%)
19 (34%)

8 (14.2%)
1 (1.7%)
7 (12.5%)
16 (28.5%)

21 (37%)

1
0
17
0
7
7

0
1
12
0
10
1

1 (2%)
1 (2%)
29 (52%)
0
17 (30%)
8 (14%)

(1.7%)
(0%)
(30.3%)
(0%)
(12.5%)
(12.5%)

(0%)
(1.7%)
(21.4%)
(0%)
(17.8%)
(1.7%)

30 (54%)

35 (63%)

3 (5.3%)
0 (0%)
3 (5.3%)
29 (51.7%)

8 (14.2%)
1 (1.7%)
7 (12.5%)
16 (28.5%)

11 (20%)

0
2
21
0
9
0

0
1
14
0
9
0

0
3
35
0
18
0

(0%)
(3.5%)
(37.5%)
(0%)
(16%)
(0%)

(0%)
(1.7%)
(25%)
(0%)
(16%)
(0%)

45 (80%)

(0%)
(5%)
(63%)
(0%)
(32%)
(0%)

(continued)
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Table 1. Continued
Case responses

Respiratory
(n ¼ 32)

Haematology/oncology
(n ¼ 24)

Total
(n ¼ 56)

Decision to insert an IVCF
Yes
Permanent
Retrievable
No

3 (5.3%)
0 (0%)
3 (5.3%)
29 (51.7%)

8 (14.2%)
1 (1.7%)
7 (12.5%)
16 (28.5%)

11 (20%)

45 (80%)

IV: intravenous; LMWH: low-molecular-weight heparin; DOAC: direct oral anticoagulant; VKA: vitamin K antagonist; IVCF: inferior vena cava filters; DOAC: direct
oral anticoagulant.
Note: Bold values refer to the total number of responses for that question. Whereas italic values show the breakdown of responses.

Table 2. Relationship between timing of anticoagulant/timing of surgery and insertion of IVCF.
Case

Insert IVCF

Immediate anticoagulation

Delayed anticoagulation

OR (95% CI)

p

Case 1

No
Yes
No
Yes

21
10
25
12

5
20
10
9

8.4 (2.44–28.9)

0.001

1.88 (0.60–5.83)

0.277

Case 2

IVCF: inferior vena cava filter.
Note: Odds ratio for inserting an IVCF, compared with choosing not to, are reported with their 95% confidence interval (95% CI).

We created four scenarios representative of dilemmas
faced by clinicians in clinical practice. All cases were adaptions of cases seen in our hospital over the previous 12
months.
In case 1, there is a compelling contraindication to anticoagulation due to the relatively high risk of an epidural
haematoma. The use of an IVCF in this setting has unanimous support from available guidelines (Fig. 3). The risk of
VTE following spinal surgery is recognised to be considerable with neurosurgery recognised as a transient risk factor
for VTE.21,22 The risks of spinal haematoma and major
complications from therapeutic anticoagulation are
high.23,24 IVCFs have been proven to reduce the rate of
recurrent PE signiﬁcantly in this situation.17 In spite of
this, 46% of respondents would not elect to insert an
IVCF in this case; 55% of respondents (15 Respiratory
Physicians and 16 Medical Oncologists/Haematologists)
elected to initiate anticoagulation therapy on Day 3 immediately upon diagnosis of VTE. This obviates the need for an
IVCF if anticoagulation is tolerated without complication.
This likely accounts for why only 46% of respondents
elected not to insert an IVCF. The American College of
Chest Physicians (ACCP) suggest resuming therapeuticdose LMWH 48–72 h after surgery.25 However no clear consensus exists from with speciﬁc regard to spinal surgery with
wide variability of surgeons’ practices.25,26
There is still an ongoing debate as to the timing of anticoagulation in patients following spinal surgery,27 with the
diﬀerences in practices evident in the responses. Of the physicians surveyed, half chose to delay anticoagulation by up to
four weeks. These physicians were eight times more likely to
insert an IVCF likely reﬂecting concerns around delayed
anticoagulation.

In case 2, a patient requires major oncological surgery in
the setting of a recent VTE. The rates of VTE recurrence
tend to be greatest following the initial month after diagnosis and remain high for 6–12 months post diagnosis.9
Conversely, delaying surgery may also have prognostic
implications from the malignancy.
Following surgery for ovarian malignancy, the postoperative VTE risk is as high as 13.5%. The development
of VTE has a negative impact on overall survival with PE
being the leading cause of death in ovarian malignancy.28,29
The type and timing of therapeutic anticoagulation has to be
balanced against the perioperative bleeding risk and the risk
of further VTE. Two retrospective case series have shown
reduced rates of PE with the use of IVCFs preoperatively in
gynaecological and other malignancies.30,31
The British Committee for Standards in Haematology
(BCSH) guidelines recommend considering IVCF use in
patients scheduled for surgery with recent VTE (<1 month)
in whom anticoagulation must be interrupted.5 This is consistent with previously published experience at our centre.19 In
this setting, there is a relative indication for IVCF use. In our
survey, only 21 (38%) of the physicians surveyed opted to
insert an IVCF, reﬂecting the lack of consensus.
We examined the relationship between timing of surgery
and the insertion of an IVCF. Numerically physicians
choosing to delay surgery by 4–6 weeks were more likely
to recommend insertion of an IVCF; however, this did not
reach statistical signiﬁcance. This likely reﬂects personal
preference and the risk-averse nature of some clinicians.
Delayed surgery was likely preferred to further mitigate
the risk of VTE in an already high-risk population. As the
risk of recurrent VTE remains highest in the month following diagnosis, delaying surgery and allowing a patient to

Pulmonary Circulation
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Fig. 3. Recommendations from international societies regarding IVCF insertion with regards to each individual case.

become established on therapy may be a reasonable
approach. Furthermore, IVCF insertion may theoretically
reduce the risks involved with the necessary interruption
of anticoagulation in the immediate perioperative period.
In the absence of anticoagulation, the risk of recurrence is
about 40% in the ﬁrst month.32 Surgery itself necessitates
the interruption of anticoagulation while in itself is a
major acquired risk factor for VTE.33 Understandably, the
BCSH guidelines consider this a relative indication for
IVCF insertion, but only based on expert opinion (Grade
C evidence).
Case 3 has two facets to consider. The ﬁrst part focuses
on the development/propagation of a thrombus despite adequate anticoagulation with a DOAC. Eleven respondents
(20%) chose to insert an IVCF of whom 10 opted to
switch to LMWH, while 1 continued with the DOAC.

In this circumstance, the Society of Interventional
Radiology/American College of Radiology (SIR/ACR),
American Heart Association (AHA) and Cardiovascular
Interventional Radiology Society of Europe (CIRSE) guidelines support the insertion of an IVCF.6–8 The ACCP guidelines however recommend against their use.4 The BCSH
guidelines recommend switching to LMWH before considering an IVCF.5 The varied responses in our survey understandably reﬂect these inconsistencies.
Mellado et al. examined the eﬀectiveness of IVCFs in the
setting of recurrent symptomatic VTE on anticoagulation.
They found a statistically signiﬁcant survival advantage for
the patients who received an IVCF whilst on systemic anticoagulation.34 This may be of particular relevance in oncology, where there is an increased risk of PE recurrence
despite anticoagulation.

8
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Fig. 4. Investigation for malignancy in the setting of recurrent VTE.
*Routine screening was defined as compliance with age/gender appropriate government run cancer screening strategies.

Table 3. Relationship between decision to insert an IVCF and specialty.
Case

Insert IVCF

Respiratory

Haematology/oncology

OR (95% CI)

p

1

No
Yes
No
Yes
No
Yes
No
Yes

11
21
19
13
29
3
24
8

15
9
16
8
16
8
20
4

3.18 (1.06–9.58)

0.040

1.37 (0.45–4.13)

0.577

0.21 (0.05–0.89)

0.034

1.67 (0.44–6.36)

0.455

2
3
4

Note: Odds ratio for inserting an IVCF compared with choosing not to, are reported with their 95% confidence interval (95% CI).

Whether to alter the dose or change anticoagulant for
VTE occurring on therapeutic anticoagulation is largely
based on expert opinion.34 Only two guidelines comment
on this. The ACCP guidelines recommend switching the
patient to a LMWH if they are on a vitamin K antagonist
and if they are already on LMWH, they recommend increasing the dose (grade 2 evidence).4 The BCSH guidelines

recommend considering an IVCF after the target INR has
been increased to 3.5 or the patient has been switched to
LMWH. As these guidelines were derived prior to the widespread use of the DOACs, the recommendation in such an
instance of DOAC failure is not known.5 Unfortunately,
The ACR/SIR, CIRSE and the AHA guidelines provide
no further advice.6–8

Pulmonary Circulation
The development of a recurrent VTE despite anticoagulation raises the suspicion of an occult malignancy.35,36
Eighty-six percent of respondents recommended investigating for an occult malignancy (Fig. 4). More than half of
physicians that we surveyed recommended performing a
CT chest/abdomen/pelvis to further investigate for malignancy. At present, the extensive investigation of malignancy
in patients with an unprovoked VTE (and in the absence of
further signs or symptoms to suggest malignancy) is not
routinely recommended, as the yield of uncovering an
underlying malignancy is low.35–37
Case 4 involves a substantial PE and DVT in the setting
of known metastatic disease in a patient undergoing chemotherapy. The presence of malignancy is an independent risk
factor for fatal PE when compared to non-cancer populations.38,39 The majority of physicians elected to anticoagulate with LMWH. Three physicians (5%) elected to
prescribe a DOAC. In our experience, the use of a DOAC
in this situation is often a pragmatic consideration based on
patient preference against prolonged injections. The DOAC
edoxaban (a Factor Xa inhibitor) has demonstrated noninferiority for treatment of malignancy associated VTE
when compared to dalteparin with an acceptable rate of
bleeding complications.40 A similar study (SELECT-D)
compared rivaroxaban (a DOAC) to dalteparin (LWMH).
Relatively low rates of VTE were seen in both arms with
more clinically relevant non-major bleeding in the rivaroxaban arm.41 Thus we believe that it is likely that DOACs will
soon become an acceptable standard of care in patients with
VTE-associated malignancy.
No current guidelines advocate for upfront IVCF insertion for large PE alone as described in case 4. In our survey,
12 (21%) respondents recommended IVCF insertion with a
third of them opting for a permanent IVCF. Oncology
patients are a unique group with the potential for heightened risk of both VTE and bleeding. The available RCTs
published to date are underpowered to guide clinical decision making in the setting of CAT. The PREPIC2 study
examined anticoagulation with or without the use of a
retrievable IVCF in 399 patients. Only 62 subjects (15%)
of those on the study had active malignancy. Another
study comparing the use of IVCF and fondaparinux (a
LMWH) with or without an IVCF had a sample size of 64
patients.20,39 The use of IVCFs in this cohort may represent
a cautious but invasive strategy to avoid hypothetical under
treatment, which is reﬂected in our survey.
Respiratory Physicians were more likely to insert an IVCF
for case 1 (PE post operatively). This case has the most compelling indication for IVCF insertion. In the absence of anticoagulation, all guidelines recommend the use of an IVCF.
With the absence of malignancy, Haematologists/Oncologists
may be less familiar with this scenario.
However, in case 3 (recurrent VTE despite anticoagulation), Haematologists/Oncologists were more likely to insert
an IVCF. This likely reﬂects the diﬀerences between guidelines. The ACCP guidelines, which would be better known
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to Respiratory Physicians, recommend against their use in
this setting. On the other hand, the BCSH would consider it
a reasonable approach to insert an IVCF in the setting of
treatment failure. While these guidelines were published in
2006, a more recent consensus from the International
Society of Thrombosis and Haemostasis (ISTH) state
IVCFs should not be systematically inserted in cancer
patients with recurrent VTE, and should be reserved for
patients with contraindications to anticoagulation.42
A detailed set of guidelines on the diagnosis and management of VTE have recently been published by Thrombosis
and Haemostasis Society of Australia and New Zealand.43
This paper was not available to respondents at the time of
surveying. The authors conduct a detailed discussion on the
assessment, diagnosis and management of VTE and agree
with our previously published supposition that the use of
DOACs is acceptable in the setting of CAT. Within the guidelines, however, there is limited discussion on the use of IVCFs
in general, nor detailed speciﬁc management of oncologyassociated VTE. We would respectfully submit that these
otherwise excellent guidelines would be improved by the presence of non-haematological physicians involved in the process
and we would recommend greater collaboration between specialists in drafting future guidelines as a positive step to ensure
a consistency of approach in this complex area of medicine.

Limitations
The major limitation of this study was the small sample size;
however, most respondents were consultants (> 77%),
which is beneﬁcial given the relative complexity of the
cases. Another potential limitation was that vascular surgeons, interventional radiologists and cardiologists were
not surveyed. In the Australian context, the decision
around insertion of temporary IVCF is primarily the remit
of Haematologists, Medical Oncologists and Respiratory
Physicians – although we accept that the responsibility for
such decisions may vary by specialty and by country.
Our survey of Australian Respiratory Physicians,
Haematologists and Oncologists highlights the variability in
the management of VTE, particularly CAT. This variability
is in part driven by inconsistencies between the available
guidelines, which in turn occurs due to gaps in the
completed research. IVCFs are an important tool in CAT
management but they have their limitations. There remains
a need for better powered studies to answer clinically relevant
questions.
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